|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2008-10-9
|
|
pubmed:abstractText |
To compare work disability and job loss in early rheumatoid arthritis (RA) patients receiving adalimumab plus methotrexate (adalimumab + MTX) versus MTX alone.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
pubmed-author:AdebajoAdeA,
pubmed-author:BejaranoVictoriaV,
pubmed-author:ConaghanPhilip GPG,
pubmed-author:DohertySheelaghS,
pubmed-author:EmeryPaulP,
pubmed-author:GoughAndrewA,
pubmed-author:GreenMichaelM,
pubmed-author:HordonLesleyL,
pubmed-author:JarrettStephenS,
pubmed-author:KeenanAnne-MareeAM,
pubmed-author:KupperHartmutH,
pubmed-author:McGonagleDennisD,
pubmed-author:MelsomRichardR,
pubmed-author:OdilaAA,
pubmed-author:RICHM PMP,
pubmed-author:ReeceRichardR,
pubmed-author:UnnebrinkKristinaK,
pubmed-author:WalkerDavidD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1467-74
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18821658-Adult,
pubmed-meshheading:18821658-Antibodies, Monoclonal,
pubmed-meshheading:18821658-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18821658-Antirheumatic Agents,
pubmed-meshheading:18821658-Arthritis, Rheumatoid,
pubmed-meshheading:18821658-Drug Therapy, Combination,
pubmed-meshheading:18821658-Early Diagnosis,
pubmed-meshheading:18821658-Employment,
pubmed-meshheading:18821658-Female,
pubmed-meshheading:18821658-Humans,
pubmed-meshheading:18821658-Kaplan-Meier Estimate,
pubmed-meshheading:18821658-Male,
pubmed-meshheading:18821658-Methotrexate,
pubmed-meshheading:18821658-Middle Aged,
pubmed-meshheading:18821658-Treatment Outcome,
pubmed-meshheading:18821658-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.
|
|
pubmed:affiliation |
University of Leeds, Leeds, UK.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
